Founded in 2013, Mifcare is a privately held biotechnology company developing breakthrough anti-inflammatory therapeutics with a primary focus on pulmonary arterial hypertension (PAH).

[Read more]

The company is specialized in the discovery and development of new small molecule antagonists of macrophage migration inhibitory factor (MIF), a pleiotropic cytokine that modulates pro-inflammatory immune responses.

[Read more]